Phase I-Ii evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma
Kane, R.C.; Cohen, M.H.; Broder, L.E.; Bull, M.I.; Creaven, P.J.; Fossieck, B.E.
Cancer ChemoTherapy Reports 59(6): 1171-1172
1975
ISSN/ISBN: 0069-0112 PMID: 1222395 Document Number: 4455
The drug-associated toxicity observed in our study is qualitatively similar to that previously reported (2-4). While the iv route of administration avoids the local discomfort associated with the sc or im route, it does not appear to alter significantly the cumulative dose-related toxicity of emetine. A moderately toxic dose of emetine suitable for weekly administration is 100-130 mg/m2. This dose produces toxicity similar to a dose of 56 mg/m2 biweekly or 37 mg/m2 daily for 10 days (4). Although one patient had a 1-month partial tumor response, the patient incurred considerable drugrelated toxic effects negating any possible clinical benefit from the treatment. Likewise, in the four patients whose disease was static." at 4 weeks but progressive at 6-9 weeks, symptomatic improvement as measured by improved performance status or weight gain did not occur concomitantly. The weekly iv schedule of therapy used in this study does not appear to result in tumor response with an acceptable degree of drug-related toxicity in epidermoid bronchogenic carcinoma.
Document emailed within 1 workday
